Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. triplecon

TRIPLECON

Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRIPLECON project word cloud

Explore the words cloud of the TRIPLECON project. It provides you a very rough idea of what is the project "TRIPLECON" about.

resistance    her2    block    receptor    pdx    aggressive    stalling    cell    cyclin    giving    chemotherapies    envisage    cdk9    causing    synergized    cancer    receptors    erc    benefit    dual    bc    agent    patients    disease    pharmacological    accounting    patient    single    outcomes    triple    safe    negative    explore    family    intrinsic    treat    benefiting    ongoing    trials    unsatisfactory    translate    breast    revealed    er    therapies    mainstay    overexpressed    proliferation    egfr    molecular    combination    models    striving    strategy    combinatorial    disproportionally    targetable    instance    therapy    synergistic    clinical    owing    lapatinib    cytotoxic    concomitantly    approved    treatment    compensatory    death    poc    strikingly    80    drive    clinic    tnbc    vivo    dysregulated    15    20    express    pr    inhibit    322737    poor    attempted    proof    mouse    xenograft    successful    epidermal    kinase    inhibitor    grant    lines    clinically    drug    dependent    signaling    forms    preliminary   

Project "TRIPLECON" data sheet

The following table provides information about the project.

Coordinator		 ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 90˙075.00
2    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 59˙925.00

Map

 Project objective

'Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer. Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies. Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance. Clinical trials have attempted to explore molecular targeted therapies to block dysregulated growth factor receptors in TNBC, for instance, epidermal growth factor receptor (EGFR), as it is overexpressed in ~80% of TNBC. Yet, giving the long-standing availability of clinically approved EGFR-targeted therapies, such as lapatinib, the clinical benefit of single agent therapy is unsatisfactory, owing to the compensatory dysregulated signaling pathways. In our ongoing ERC – Advanced Grant Triple-BC (#322737) we are striving to explore combinatorial molecular targeted therapies to concomitantly block the identified dysregulated signaling pathways. Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergized with targeting EGFR receptor family signaling to inhibit cell proliferation of TNBC cell lines. The overall goal of this PoC project is to exploit this novel finding and provide proof-of-concept evidence that stalling CDK9 signaling may enable successful targeted combination therapy in TNBC. Therefore, the specific objective is to assess the pharmacological response of dual EGFR-CDK9 targeting in TNBC patient-derived xenograft (PDX) mouse models in vivo. We envisage that this PoC project will translate our identified successful synergistic treatment into an effective future novel and safe combinatorial targeting strategy benefiting TNBC patients.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIPLECON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIPLECON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More